Erythropoiesis-stimulating agents (ESAs) were combined with ruxolitinib in 59 anaemic myelofibrosis patients (93% with Dynamic International Prognostic Scoring System [DIPSS] intermediate-2/high risk; 52·5% transfusion-dependent). Anaemia response (AR) rate was 54% and 76% of patients responded at 5 years. A further 15% displayed minor improvement in anaemia and 78% of patients reduced spleen size. Endogenous erythropoietin levels <125 u/l correlated with a higher AR rate (63% vs. 20%, P = 0·008). No thrombotic events or other toxicities occurred. Overall survival was 62% at 4 years, influenced by DIPSS and transfusion dependency. ESAs seem effective in improving anaemia in ruxruxolitinib-treated myelofibrosis patients.

The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib / Crisà, Elena; Cilloni, Daniela; Elli, Elena M.; Martinelli, Vincenzo; Palumbo, Giuseppe A.; Pugliese, Novella; Beggiato, Eloise; Frairia, Chiara; Cerrano, Marco; Lanzarone, Giuseppe; Marchetti, Monia; Mezzabotta, Mauro; Boccadoro, Mario; Ferrero, Dario. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 182:5(2018), pp. 701-704. [10.1111/bjh.15450]

The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib

Martinelli, Vincenzo;Palumbo, Giuseppe A.;Pugliese, Novella;
2018

Abstract

Erythropoiesis-stimulating agents (ESAs) were combined with ruxolitinib in 59 anaemic myelofibrosis patients (93% with Dynamic International Prognostic Scoring System [DIPSS] intermediate-2/high risk; 52·5% transfusion-dependent). Anaemia response (AR) rate was 54% and 76% of patients responded at 5 years. A further 15% displayed minor improvement in anaemia and 78% of patients reduced spleen size. Endogenous erythropoietin levels <125 u/l correlated with a higher AR rate (63% vs. 20%, P = 0·008). No thrombotic events or other toxicities occurred. Overall survival was 62% at 4 years, influenced by DIPSS and transfusion dependency. ESAs seem effective in improving anaemia in ruxruxolitinib-treated myelofibrosis patients.
2018
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib / Crisà, Elena; Cilloni, Daniela; Elli, Elena M.; Martinelli, Vincenzo; Palumbo, Giuseppe A.; Pugliese, Novella; Beggiato, Eloise; Frairia, Chiara; Cerrano, Marco; Lanzarone, Giuseppe; Marchetti, Monia; Mezzabotta, Mauro; Boccadoro, Mario; Ferrero, Dario. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 182:5(2018), pp. 701-704. [10.1111/bjh.15450]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/742077
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 19
social impact